It seems that every week brings another round of vaccine hopes. This week’s top news concerns Moderna’s reported 94.5% effective vaccine candidate. The now-familiar ripples throughout the markets have lifted oil and travel stocks, while attacking the tech sector. Buy and sell opportunities abound.
Work from home stocks take a hit
Tech stocks are taking a hit – primarily those that have seen big momentum this year from the near-term “work from home” growth thesis. Canada’s top TSX ecommerce stock, Shopify, was down by around 2% on the news, opening a value opportunity. U.S. stocks such as Zoom, Peloton, Amazon, and Home Depot were also trending lower. It has been evident since the summer that tech stocks are allergic to vaccine breakthroughs.
Value stocks got some attention, though, with Air Canada up 3.8% and Cineplex adding 9.8%. Other chewed-up names also saw gains Monday. Manulife Financial, one of the insurance industry’s widest of wide moat stocks, climbed 2%. CNQ rose 2.9%, providing further evidence that a vaccine rollout could be good news in the near-term for hydrocarbon stocks.
Investors may want to start making buy and sell lists, including key entry and exit points, specifically for the vaccine market. Last week’s early statement alleging that Pfizer and BioNTech had created a coronavirus vaccine showing 90% effectiveness blasted the markets into the stratosphere. If this behaviour can now be predicted, opportunities to build and trim could be about to come thick and fast.
5 Stocks Under $49 (FREE REPORT)Click here to gain access!
Expect high short-term volatility in stocks
While build and trim opportunities are great, the danger in the market comes when investors trust those bull runs. Everybody is waiting for an end to the pandemic. A vaccine – or, indeed, multiple vaccines – will logical bring an end to the health crisis. But we’re not out of the woods yet. Until we are, headline-grabbing breakthroughs are good for a bit of momentum. Indeed, last week’s bull run offered a taste of things to come.
But even that bullishness proved premature. Further news came to light by midweek: Pfizer’s CEO had (apparently legally) cashed in US$5.6 million of shares. We also learned that complex storage systems may be required to keep the vaccine candidate at its requisite -70 degrees Celsius. A week has become a long time in investing, and by Friday, the bull run was showing signs of withering.
The names that rallied have largely been floundering all year, and the “buy” thesis was tenuous at best. With cases rising and political uncertainty lingering just across the border, TSX investors have to temper their near-term expectations. Now it seems that every week we’re to be treated to a different vaccine rally from a different Big Pharma outfit. It’s almost become a stand-in stimulus program.
Bullishness is all well and good. It brings opportunities to ride upside, while other investors can short certain names and buy back cheaper after the inevitable post-rip dip. For the lower-risk investor, long positions can be built gradually while red ink predominates. And while shareholders see underperforming tickers splashed with green, there are chances to raise liquidity.
Buying quality stocks for retirement? The following report could significantly improve your portfolio!
Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. David Gardner owns shares of Amazon. Tom Gardner owns shares of Shopify and Zoom Video Communications. The Motley Fool owns shares of and recommends Amazon, Home Depot, Peloton Interactive, Shopify, Shopify, and Zoom Video Communications and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon.